(0.62%) 5 077.75 points
(0.35%) 38 204 points
(0.87%) 17 591 points
(0.70%) $79.55
(2.38%) $1.978
(-0.23%) $2 305.60
(-1.24%) $26.42
(0.31%) $957.90
(0.12%) $0.934
(0.47%) $11.08
(0.08%) $0.799
(-1.49%) $91.87
0.92% € 61.64
Live Chart Being Loaded With Signals
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally...
Stats | |
---|---|
Tagesvolumen | 1 160.00 |
Durchschnittsvolumen | 1 068.00 |
Marktkapitalisierung | 76.86B |
EPS | €0 ( 2024-04-25 ) |
Last Dividend | €0.750 ( 2023-09-14 ) |
Next Dividend | €0 ( N/A ) |
P/E | 181.29 |
ATR14 | €0.175 (0.28%) |
Gilead Sciences Inc Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Gilead Sciences Inc Finanzdaten
Annual | 2023 |
Umsatz: | €27.12B |
Bruttogewinn: | €20.62B (76.04 %) |
EPS: | €4.54 |
FY | 2023 |
Umsatz: | €27.12B |
Bruttogewinn: | €20.62B (76.04 %) |
EPS: | €4.54 |
FY | 2022 |
Umsatz: | €27.28B |
Bruttogewinn: | €21.62B (79.26 %) |
EPS: | €3.66 |
FY | 2021 |
Umsatz: | €27.31B |
Bruttogewinn: | €20.70B (75.82 %) |
EPS: | €4.95 |
Financial Reports:
No articles found.
Gilead Sciences Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.730 (N/A) |
€0.730 (N/A) |
€0.750 (N/A) |
€0.750 (N/A) |
€0.750 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.430 | 2015-06-12 |
Last Dividend | €0.750 | 2023-09-14 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 34 | -- |
Total Paid Out | €20.74 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.24 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.30 | |
Div. Directional Score | 8.00 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
UN9.DE | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
DTG.DE | Ex Dividend Junior | 2023-06-22 | Insufficient data to determine frequency | 0 | 0.00% | |
NCB.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
7BP.F | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% | |
YCP.DE | Ex Dividend King | 2023-09-27 | Bi-Monthly | 0 | 0.00% | |
FNTN.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
PHM7.DE | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
ARL.DE | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
HMSB.DE | Ex Dividend Knight | 2023-11-09 | Annually | 0 | 0.00% | |
SIX2.DE | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.209 | 1.500 | 5.82 | 8.73 | [0 - 0.5] |
returnOnAssetsTTM | 0.0912 | 1.200 | 6.96 | 8.35 | [0 - 0.3] |
returnOnEquityTTM | 0.260 | 1.500 | 8.22 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.672 | -1.000 | 3.28 | -3.28 | [0 - 1] |
currentRatioTTM | 1.426 | 0.800 | 7.87 | 6.30 | [1 - 3] |
quickRatioTTM | 1.057 | 0.800 | 8.49 | 6.79 | [0.8 - 2.5] |
cashRatioTTM | 0.539 | 1.500 | 8.11 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.402 | -1.500 | 3.30 | -4.94 | [0 - 0.6] |
interestCoverageTTM | 8.06 | 1.000 | 8.13 | 8.13 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.42 | 2.00 | 7.86 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.95 | 2.00 | 7.03 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.094 | -1.500 | 5.62 | -8.43 | [0 - 2.5] |
grossProfitMarginTTM | 0.760 | 1.000 | 0.661 | 0.661 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.280 | 1.000 | 6.39 | 6.39 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.320 | 1.000 | 9.33 | 9.33 | [0.2 - 2] |
assetTurnoverTTM | 0.436 | 0.800 | -0.424 | -0.339 | [0.5 - 2] |
Total Score | 10.70 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.42 | 1.000 | 8.64 | 0 | [1 - 100] |
returnOnEquityTTM | 0.260 | 2.50 | 8.86 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.95 | 2.00 | 8.02 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.61 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.42 | 2.00 | 7.86 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.672 | 1.500 | 3.28 | -3.28 | [0 - 1] |
pegRatioTTM | -0.0684 | 1.500 | -3.79 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.295 | 1.000 | 5.12 | 0 | [0.1 - 0.5] |
Total Score | 5.30 |
Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.